百济神州:泽布替尼新剂型预计今年下半年在欧美获批

医药魔方
08 May

5月7日, 百济神州 发布2025Q1财报,其产品收入为79.85亿元,同比增长49.9%;公司营业总收入为80.48亿元,同比增长50.2%;2025年第一季度归属于母公司所有者的净利润为-0.95亿元。泽布替尼(百悦泽)2025Q1的全球销售额总计56.92亿元,同比增长63.7%。而根据阿斯利康财报,阿可替尼2025Q1的全球销售额为7.62亿美元(1美元=7.1829元人民币,约合...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10